Navigation Links
Bacteria use lethal cytotoxins to evade antibiotic treatment
Date:11/18/2013

In spite of the fact that the first antibiotics were discovered almost a century ago, infectious diseases such as tuberculosis, encephalitis and meningitis are still serious diseases for humans in the twenty-first century. The World Health Organization (WHO) estimates that there are more than 8 million new cases of tuberculosis per year on a global scale, and that more than 300,000 of these are due to multidrug-resistant strains that are not only difficult to treat, but are also emerging rapidly in regions such as Eastern Europe.

Bacterial tolerance is not just due to resistance, but also to the formation of persistent cells that have gone into a dormant state where they are no longer sensitive to antibiotics. On the molecular level, this process is controlled by a number of advanced cytotoxins produced by the bacteria themselves in order to survive. In Mycobacterium tuberculosis the organism that causes tuberculosis there are no fewer than 88 such toxins, all of which presumably help the organism to survive.

In a new article in the renowned journal Nature Communications, an international team of researchers with the participation of the Department of Molecular Biology and Genetics, Aarhus University, has revealed the mechanism behind one of these toxins VapC20. It turns out that when the toxin is activated, it destroys the tuberculosis bacteria's own protein 'factory' (the ribosome) by cleavage. The bacteria are thereby unable to produce proteins in the short term, and thus avoid the effect of antibiotics that also often attack the ribosome.

When treatment with antibiotics is completed, the pathogenic bacteria 'wake up' and are ready to synthesise new ribosomes. Surprisingly, it appears that the location in the ribosome that is cleaved by VapC20 is the same place that is destroyed by the strong cytotoxins α-sarcin and ricin, which are found in plants such as castor beans and are twice as venomous as cobra snake poison.

Further analysis of the cleavage point in the ribosome also shows that the mechanism is presumably general for a number of the many toxins, and the new knowledge could therefore be used in future to develop new ways of treating pathogenic bacteria by impairing their ability to use such cytotoxins.


'/>"/>

Contact: Ditlev E. Brodersen
deb@mb.au.dk
45-21-66-90-01
Aarhus University
Source:Eurekalert  

Related biology news :

1. Leading evolutionary scientist to discuss how genome of bacteria has evolved
2. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
3. Team discovers how bacteria resist a Trojan horse antibiotic
4. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
5. Bacterial shock to recapture essential phosphate
6. Disarming disease-causing bacteria
7. Study shows unified process of evolution in bacteria and sexual eukaryotes
8. Invisible helpers: How probiotic bacteria protect against inflammatory bowel diseases
9. Researchers develop rapid test strips for bacterial contamination in swimming water
10. Bacteria discovery could lead to antibiotics alternatives
11. Agricultural bacteria: Blowing in the wind
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Bacteria use lethal cytotoxins to evade antibiotic treatment
(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/22/2016)... , June 22, 2016  The American College of Medical ... Show Executive Magazine as one of the fastest-growing trade ... 25-27 at the Bellagio in Las Vegas ... highest percentage of growth in each of the following categories: ... companies and number of attendees. The 2015 ACMG Annual Meeting ...
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... India , June 23, 2016 ... media market research report to its pharmaceuticals section ... profiles, product details and much more. ... spread across 151 pages, profiling 15 companies and ... available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology: